Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Jacques Chitte who wrote (3144)	3/27/1998 9:19:00 PM
From: Doug Shapiro	Respond to of 7041

Based on the 10Q from Sept 97 and the cash on hand at that time I estimate the book value of Zonagen at $6.87. That is if they have not spent any since Sept. 97. This does not take into account the payouts to the class actions filed against the company. The lawyers are going to bleed this company dry. Zonagen does not have any real revenue to speak of certainly not enough to cover expences of development of vasomax. My prediction Zonagen goes flaccid! Doug

To: Jacques Chitte who wrote (3144)	3/28/1998 9:29:00 PM
From: Ploni	Read Replies (1) \| Respond to of 7041

On what revenue are these earnings based, if Vasomax is gonna be slow to market? Zona reports earnings this Wednesday. Estimates are $.44. That's four and a half million dollars on the plus side. From what? Here's the deal: (a) Start a company (b) Sell stock (c) Use some of the proceeds to pay yourself, plus you'll still own plenty of stock which you can sell from time-to-time (d) Put the rest of the proceeds from the stock sale in the bank (e) The bank pays you interest income (f) No you can report income. Revenues are not necessary. This trick has worked for many companies, such as YHOO.